Gilead Sciences, Inc. $GILD Position Reduced by Venture Visionary Partners LLC

Venture Visionary Partners LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 53.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,381 shares of the biopharmaceutical company’s stock after selling 7,391 shares during the period. Venture Visionary Partners LLC’s holdings in Gilead Sciences were worth $715,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC acquired a new position in Gilead Sciences in the first quarter worth approximately $25,000. Goodman Advisory Group LLC acquired a new position in Gilead Sciences in the first quarter worth approximately $29,000. Colonial Trust Advisors grew its position in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 213 shares during the last quarter. Core Alternative Capital grew its position in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 241 shares during the last quarter. Finally, IMA Advisory Services Inc. acquired a new position in Gilead Sciences in the first quarter worth approximately $39,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of several recent research reports. Morgan Stanley lifted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, April 25th. UBS Group lifted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research report on Friday, August 8th. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a research report on Friday, July 25th. Finally, Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $115.39.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the transaction, the chief executive officer owned 605,725 shares in the company, valued at $69,016,306.50. This trade represents a 1.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,000 shares of company stock worth $9,339,230. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 0.6%

GILD stock opened at $118.73 on Thursday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 1 year low of $74.80 and a 1 year high of $121.83. The company has a fifty day simple moving average of $112.33 and a 200 day simple moving average of $108.78. The firm has a market cap of $147.32 billion, a PE ratio of 23.65, a PEG ratio of 0.72 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the business earned $2.01 EPS. Gilead Sciences’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.